

functions under physiological and pathological conditions and provide opportunities to develop new diagnostic and therapeutic approaches in clinical practice.

Main Part

Molecular Structure of GLUTs and Their Transport Mechanism

Glucose transporters (GLUTs) are integral membrane proteins typically composed of 12 transmembrane domains. Their structural organization enables the passive transport of glucose across the cell membrane. The transport mechanism operates through the “alternating conformation” model, in which the transporter protein shifts between outward-facing and inward-facing conformations, thereby allowing glucose to move into or out of the cell (Mueckler & Thorens, 2013).

GLUT1 and GLUT3 possess high affinity for glucose, ensuring efficient transport even when intracellular glucose levels are low. In contrast, GLUT2 has a low affinity but a high transport capacity, enabling rapid glucose movement in tissues such as the liver and kidneys, where glucose concentrations fluctuate widely. GLUT4 is an insulin-regulated transporter that translocates to the cell membrane in response to insulin signaling, facilitating glucose uptake in skeletal muscle and adipose tissue (Zhou et al., 2008).

The transport mechanism occurs without energy expenditure, meaning that GLUTs mediate passive transport. Additionally, the molecular structure and conformational dynamics of these transporters allow glucose to be moved efficiently at high rates. During transport, specific transmembrane domains recognize glucose as a ligand and ensure its selective movement across the membrane.

These molecular features play a crucial role in maintaining cellular energy balance, regulating metabolic pathways, and enabling adaptation to varying physiological demands. Therefore, the structure of GLUTs directly determines their functional capabilities.

Substrate Specificity and Tissue-Specific Expression

GLUTs vary in their ability to transport different monosaccharides, with each isoform exhibiting a unique substrate specificity. GLUT1 and GLUT3 have a high affinity for glucose, ensuring sufficient energy supply in tissues such as the nervous system and erythrocytes, where energy demand is constant and critical (Simpson et al., 2007). GLUT2, with its low affinity but high capacity, performs rapid glucose transport in the liver, kidneys, and enterocytes, playing a vital role in maintaining systemic glycemic balance.

GLUT4 is an insulin-responsive transporter expressed primarily in skeletal muscle and adipose tissue. When insulin signaling increases, GLUT4 translocates to the cell membrane, enabling glucose entry and activating glycolysis. GLUT5, which has high specificity for fructose, functions in intestinal enterocytes to facilitate the absorption of dietary fructose (Douard & Ferraris, 2008).

study provided a systematic analysis of GLUT molecular structure, transport mechanisms, substrate specificity, and clinical significance.

Overall, research on GLUTs contributes to a deeper understanding of metabolic and neoplastic diseases, improvement of diagnostic tools, and development of personalized therapeutic strategies. Future studies may explore the potential of modulating GLUT expression to reduce metabolic dysfunction and control the energetic adaptation of cancer cells. Moreover, uncovering molecular mechanisms related to GLUTs will be essential for designing new drug candidates.

References:

1. Mueckler M. Facilitative glucose transporters. *European Journal of Biochemistry*. 1994;219(3):713–725.
2. Thorens B. GLUT2, glucose sensing and glucose homeostasis. *Diabetes & Metabolism*. 2015;41(3):185–192.
3. Simpson IA, Carruthers A, Vannucci SJ. Supply and demand in cerebral glucose metabolism: role of glucose transporters. *Journal of Cerebral Blood Flow & Metabolism*. 2007;27(11):1515–1535.
4. Zhou Q, et al. Regulation of GLUT4 translocation in skeletal muscle. *Cell Metabolism*. 2008;8(3):237–247.
5. Douard V, Ferraris RP. Regulation of the fructose transporter GLUT5 in health and disease. *American Journal of Physiology-Endocrinology and Metabolism*. 2008;295:E227–E237.
6. De Vivo DC, et al. Glucose transporter type 1 deficiency syndrome: new pediatric and adult phenotypes. *Journal of Pediatrics*. 1991;119(6):823–831.
7. Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. *Journal of Cellular Physiology*. 2005;202:654–662.
8. Mueckler M, Thorens B. The SLC2 (GLUT) family of membrane transporters. *Molecular Aspects of Medicine*. 2013;34:121–138.
9. Kaestner KH, et al. Role of GLUT transporters in health and disease. *Annual Review of Nutrition*. 2013;33:1–25.